哺乳动物雷帕霉素靶点与自身免疫性溶血性贫血发生的研究进展

国际输血及血液学杂志 Pub Date : 2019-11-20 DOI:10.3760/CMA.J.ISSN.1673-419X.2019.06.014

Y. Wang

{"title":"哺乳动物雷帕霉素靶点与自身免疫性溶血性贫血发生的研究进展","authors":"Y. Wang","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.06.014","DOIUrl":null,"url":null,"abstract":"Mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase that is involved in the immune pathogenesis of autoimmune hemolytic anemia (AIHA) by regulating different types of T cell, B cells and dendritic cells (DC). mTOR inhibitor acts on the mTOR signaling pathway. It can up-regulate the number of regulatory T cell (Treg) and down-regulate the number of helper T cell (Th), Th2, and Th17. It plays an important role in the treatment of recurrent/refractory AIHA. The authors review the molecular structure of mTOR, mTOR signaling pathway, the regulation of mTOR involved in immune cells, and the treatment of AIHA with mTOR inhibitors. \n \n \nKey words: \nTOR serine-threonine kinases; Anemia, hemolytic, autoimmune; T-lymphocytes, regulatory; Th1 cells; Molecular targeted therapy; Immunosuppressive agents","PeriodicalId":13774,"journal":{"name":"国际输血及血液学杂志","volume":"42 1","pages":"543-547"},"PeriodicalIF":0.0000,"publicationDate":"2019-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Research progress of mammalian target of rapamycin and occurence of autoimmune hemolytic anemia\",\"authors\":\"Y. Wang\",\"doi\":\"10.3760/CMA.J.ISSN.1673-419X.2019.06.014\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase that is involved in the immune pathogenesis of autoimmune hemolytic anemia (AIHA) by regulating different types of T cell, B cells and dendritic cells (DC). mTOR inhibitor acts on the mTOR signaling pathway. It can up-regulate the number of regulatory T cell (Treg) and down-regulate the number of helper T cell (Th), Th2, and Th17. It plays an important role in the treatment of recurrent/refractory AIHA. The authors review the molecular structure of mTOR, mTOR signaling pathway, the regulation of mTOR involved in immune cells, and the treatment of AIHA with mTOR inhibitors. \\n \\n \\nKey words: \\nTOR serine-threonine kinases; Anemia, hemolytic, autoimmune; T-lymphocytes, regulatory; Th1 cells; Molecular targeted therapy; Immunosuppressive agents\",\"PeriodicalId\":13774,\"journal\":{\"name\":\"国际输血及血液学杂志\",\"volume\":\"42 1\",\"pages\":\"543-547\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-11-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"国际输血及血液学杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.06.014\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"国际输血及血液学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.06.014","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

哺乳动物雷帕霉素靶蛋白(mTOR)是一种丝氨酸/苏氨酸蛋白激酶，通过调节不同类型的T细胞、B细胞和树突状细胞(DC)参与自身免疫性溶血性贫血(AIHA)的免疫发病。mTOR抑制剂作用于mTOR信号通路。上调调节性T细胞(Treg)的数量，下调辅助性T细胞(Th)、Th2、Th17的数量。它在复发/难治性AIHA的治疗中起着重要作用。本文就mTOR的分子结构、mTOR信号通路、mTOR在免疫细胞中的调控作用以及mTOR抑制剂治疗AIHA的研究进展进行综述。关键词:TOR丝氨酸-苏氨酸激酶;贫血、溶血、自身免疫;t淋巴球,监管;Th1细胞;分子靶向治疗;免疫抑制药物

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Research progress of mammalian target of rapamycin and occurence of autoimmune hemolytic anemia

Mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase that is involved in the immune pathogenesis of autoimmune hemolytic anemia (AIHA) by regulating different types of T cell, B cells and dendritic cells (DC). mTOR inhibitor acts on the mTOR signaling pathway. It can up-regulate the number of regulatory T cell (Treg) and down-regulate the number of helper T cell (Th), Th2, and Th17. It plays an important role in the treatment of recurrent/refractory AIHA. The authors review the molecular structure of mTOR, mTOR signaling pathway, the regulation of mTOR involved in immune cells, and the treatment of AIHA with mTOR inhibitors. Key words: TOR serine-threonine kinases; Anemia, hemolytic, autoimmune; T-lymphocytes, regulatory; Th1 cells; Molecular targeted therapy; Immunosuppressive agents

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

国际输血及血液学杂志

自引率

0.00%

发文量

10610

期刊介绍： The International Journal of Transfusion and Hematology was founded in September 1978. It is a comprehensive academic journal in the field of transfusion and hematology, supervised by the National Health Commission and co-sponsored by the Chinese Medical Association, West China Second Hospital of Sichuan University, and the Institute of Transfusion Medicine of the Chinese Academy of Medical Sciences. The journal is a comprehensive academic journal that combines the basic and clinical aspects of transfusion and hematology and is publicly distributed at home and abroad. The International Journal of Transfusion and Hematology mainly reports on the basic and clinical scientific research results and progress in the field of transfusion and hematology, new experiences, new methods, and new technologies in clinical diagnosis and treatment, introduces domestic and foreign research trends, conducts academic exchanges, and promotes the development of basic and clinical research in the field of transfusion and hematology.